Skip to main content
Sopharma Trading AD logo

Sopharma Trading AD — Investor Relations & Filings

Ticker · SFT ISIN · BG1100086070 LEI · 549300TWQWLJIPYNG883 BSOBGN Wholesale and retail trade
Open in API
Filings indexed 31 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country BG Bulgaria
Listing BSOBGN SFT

About Sopharma Trading AD

https://www.sopharmatrading.com/?lang=bg

Sopharma Trading AD is a leading, fully integrated provider of healthcare services specializing in the distribution of pharmaceutical products. The company engages in the wholesale and retail trade of medicinal products, drugs, and other healthcare items. It operates a network of modern distribution centers equipped with automated warehouse management systems to ensure comprehensive market coverage and efficient logistics. Serving the pharmaceutical sector, including pharmacies and hospitals, the company is a key distributor with a strong presence in Southeastern Europe. As part of the broader Sopharma Group, a major pharmaceutical manufacturer, it leverages group synergies to offer a wide portfolio of products and services to its customers.

Recent filings

Filing Released Lang Actions
682930-KFN - annual 2025.xlsx
Regulatory Filings
2026-04-23 Bulgarian
549300TWQWLJIPYNG883-20251231-BG-CON.xhtml
Annual Report Classification · 100% confidence The document contains detailed consolidated financial statements including comprehensive income, financial position, cash flows, and changes in equity for the period ending December 31, 2025. It includes notes, auditor's signatures, and management signatures dated April 2026. The length is substantial (15,000 characters), and the content is the full financial report, not just an announcement or certification. The presence of detailed financial data, notes, and auditor's report indicates this is the official annual report covering the company's full financial performance for the fiscal year. Therefore, the document is classified as an Annual Report (10-K).
2026-04-23 Bulgarian
678667-FS_SPT_page1-4_Q4_2025-dn.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive financial report for Sopharma Trading AD, specifically titled 'Interim Consolidated Financial Report' (Междинен консолидиран отчет) for the period ending December 31, 2025. It includes detailed financial statements such as the Statement of Comprehensive Income, Statement of Financial Position, Statement of Changes in Equity, and Statement of Cash Flows, along with references to notes (Приложения). It is not an announcement or a summary, but the full interim financial report itself. FY 2025
2026-02-26 Bulgarian
678668-2.FS Notes_Group_SopharmaTrading_Q4_2025.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a comprehensive 'Interim Consolidated Financial Report' (Междинен консолидиран финансов отчет) for Sopharma Trading Group as of 31.12.2025. It contains detailed financial statements (Comprehensive Income, Financial Position, Cash Flows, Changes in Equity) and extensive notes to the financial statements, which is characteristic of an interim report rather than a simple earnings release or announcement. It meets the criteria for an Interim/Quarterly Report (IR). FY 2025
2026-02-26 Bulgarian
678677-Naredba 2 - Conso_Q4 2025_f.pdf
Regulatory Filings Classification · 95% confidence The document is a quarterly disclosure report for Sopharma Trading AD, covering the fourth quarter of 2025. It follows the regulatory requirements (Appendix 4 to Art. 12, para 1, item 1 of Ordinance No. 2) for periodic reporting of significant events, changes in control, legal proceedings, and auditor information. While it is a periodic report, it does not contain the full financial statements (balance sheet, income statement, etc.) required for an 'Interim Report' (IR) classification. Instead, it serves as a mandatory regulatory disclosure of material events for the quarter. Therefore, it is best classified as a Regulatory Filing (RNS). Q4 2025
2026-02-26 Bulgarian
678674-Additional - Conso_Q4 2025f_.pdf
Management Reports Classification · 95% confidence The document is a formal 'Additional Information' report (Допълнителна информация) filed by Sopharma Trading for the fourth quarter of 2025, pursuant to Article 12, Paragraph 4, Item 1 of Ordinance No. 2. It provides detailed management-level disclosures regarding accounting policies, organizational changes, major shareholdings, director shareholdings, legal proceedings, and intercompany loans/guarantees. This content constitutes a management discussion and analysis of the company's status and financial activities for the period, which aligns with the 'Management Reports' (MDA) category.
2026-02-26 Bulgarian

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.